First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients…
FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third…